Contraception
Volume 81, Issue 1 , Pages 1-7 , January 2010

Mifepristone: ten years later

  • Eric A. Schaff

      Affiliations

    • Corresponding Author InformationTel.: +1 585 233 2124; fax: +1 866 585 0371.
    • Formerly affiliated with Department of Family Medicine, University at Buffalo, Buffalo, NY, USA.

Received 17 May 2009 ,Revised 19 July 2009 ,Accepted 11 August 2009.

References 

  1. http://www.who.int/reproductivehealth/topics/unsafe_abortion/hrpwork/en/index.html [accessed June 18, 2009].
  2. Singh S. Hospital admissions resulting from unsafe abortion: estimates from 13 developing countries. Lancet. 2006;368:1887–1892
  3. Bartlett LA, Berg CJ, Shulman HB, et al. Risk factors for legal induced abortion-related mortality in the United States. Obstet Gynecol. 2004;103:729–737
  4. Jones RK, Zolna MR, Henshaw SK, Finer LB. Abortion in the United States: incidence and access to services, 2005. Perspect Sexual Repro Health. 2008;40:6–16
  5. Jones RJ, Henshaw SK. Mifepristone for early medical abortion: experiences in France, Great Britain and Sweden. Perspect Sexual Repro Health. 2002;34:154–161
  6. WHO. Essential Medicines, WHO Model List 20 (14th edition, revised March 2005) at http://www.who.int/medicines/publications/08_ENGLISH_indexFINAL_EML15.pdf [accessed May 17, 2009].
  7. Birgerson L, Odlind V. Early pregnancy termination with antiprogestins: a comparative clinical study of RU 486 given in two dose regimens and Epostane. Fertil Steril. 1987;48:565–570
  8. Creinin MD, Vittinghoff E, Keder L, Darney PD, Tiller G. Methotrexate and misoprostol for early abortion: a multicenter trial. I. Safety and efficacy. Contraception. 1996;53:321–327
  9. Wiebe E, Dunn S, Guilbert E, Jacot F, Lugtig L. Comparison of abortions induced by methotrexate or mifepristone followed by misoprostol. Obstet Gynecol. 2002;99(5 Pt 1):813–819
  10. Creinin MD, Vittinghoff E. Methotrexate and misoprostol vs misoprostol alone for early abortion. A randomized controlled trial. JAMA. 1994;272:1190–1195
  11. Schaff EA, Eisinger SH, Franks P, Kim SS. Methotrexate and misoprostol for early abortion. Fam Med. 1996;28:198–203
  12. Spitz IM, Bardin CW, Benton L, Robbins A. Early pregnancy termination with mifepristone and misoprostol in the United States. NEJM. 1998;338:1241–1247
  13. Ashok PW, Penney GC, Flett GM, Templeton A. An effective regimen for early medical abortion: a report of 2000 consecutive cases. Hum Reprod. 1998;13:2962–2965
  14. Zieman M, Fong SK, Benowitz NL, Banskter D, Darney PD. Absorption kinetics of misoprostol with oral or vaginal administration. Obstet Gynecol. 1997;90:88–92
  15. Middleton T, Schaff E, Fielding SL, et al. Randomized trial of mifepristone and buccal or vaginal misoprostol for abortion through 56 days of last menstrual period. Contraception. 2005;72:328–332
  16. http://www.acog.org/publications/patient_education/bp043.cfm [accessed June 18, 2009].
  17. http://www.guideline.gov/summary/summary.aspx?ss=15&doc_id=12522&nbr=6446 [accessed June 18, 2009].
  18. http://www.rcog.org.uk/womens-health/clinical-guidance/about-abortion-care-what-you-need-know [accessed June 18, 2009].
  19. http://whqlibdoc.who.int/publications/2006/9241594845_eng.pdf [accessed June 18, 2009].
  20. http://codes.ohio.gov/orc/2919.123 [accessed June 14, 2009].
  21. http://en.wikipedia.org/wiki/Off-label_use [accessed September 20, 2009].
  22. http://www.earlyoptionpill.com/section/health_professionals/providing_mifeprex and http://www.earlyoptionpill.com/userfiles/file/MedicationGuide071905.pdf [accessed September 20, 2009].
  23. Holmgren K. Women's evaluation of three early abortion methods. Acta Obstet Gynecol Scand. 1992;71:616–623
  24. Schaff EA, Fielding SL, Westhoff C, et al. Vaginal misoprostol administered 1, 2, or 3 days after mifepristone for early medical abortion: a randomized trial. JAMA. 2000;284:1948–1953
  25. Creinin MD, Fox MC, Teal S, Chen A, Schaff EA, Meyn LA, et al. A randomized comparison of misoprostol 6–8 hours versus 24 hours after mifepristone for abortion. Obstet Gynecol. 2004;103(5 Pt 1):851–859
  26. Creinin MD, Schreiber CA, Bednarek P, Lintu H, Wagner MS, Meyn LA, et al. Mifepristone and misoprostol administered simultaneously versus 24 hours apart for abortion: a randomized controlled trial. Obstet Gynecol. 2007;109:885–894
  27. el-Refaey H, Rajasekar D, Abdalla M, Calder L, Templeton A. Induction of abortion with mifepristone (RU 486) and oral or vaginal misoprostol. NEJM. 1995;332:983–987
  28. Clark W, Panton T, Hann L, Gold M. Medication abortion employing routine sequential measurements of serum hCG and sonography only when indicated. Contraception. 2007;75:131–135
  29. Winikoff B, Sivin I, Coyaji KJ, et al. Safety, efficacy, and acceptability of medical abortion in China, Cuba, and India: a comparative trial of mifepristone–misoprostol versus surgical abortion. Am J Obstet Gynecol. 1997;176:431–437
  30. Elul B, Hajri S, Ngoc NN, et al. Can women in less-developed countries use a simplified medical abortion regimen. Lancet. 2001;357:1402–1405
  31. Wu S. Medical abortion in China. J Am Med Womens Assoc 2004;55(3 Suppl):197--179, 204.
  32. Parashar P, Iversen OE, Midboe G, Myking O, Bjorge L. Medical abortion in the first trimester: the use of serum hCG and endometrial thickness as markers of completeness. Eur J Contracept Reprod Health Care. 2007;12:366–371
  33. Marrs RP, Kletzky OA, Howard WF, Mishell DR. Disappearance of human chorionic gonadotropin and resumption of ovulation following abortion. Am J Obstet Gynecol. 1979;135:731–736
  34. Godfrey EM, Anderson A, Fielding SL, Meyn L, Creinin MD. Clinical utility of urine pregnancy assays to determine medical abortion outcome is limited. Contraception. 2007;75:378–382
  35. Clark WH, Gold M, Grossman D, Winikoff B. Can mifepristone medical abortion be simplified? A review of the evidence and questions for future research. Contraception. 2007;75:245–250
  36. WHO Task Force on Post-ovulatory Methods of Fertility Regulation . Comparison of two doses of mifepristone in combination with misoprostol for early medical abortion: a randomised trial. Br J Obstet Gynaecol. 2000;107:524–530
  37. Kapp N, Borgatta L, Ellis SC, Stubblefield P. Simultaneous very low dose mifepristone and vaginal misoprostol for medical abortion. Contraception. 2006;73:525–527
  38. Liao AH, Han XJ, Wu SY, Xiao DZh, Xiong CL, Wu XR. Randomized, double-blind, controlled trial of mifepristone in capsule versus tablet form followed by misoprostol for early medical abortion. Eur J Obstet Gynecol Reprod Biology. 2004;116:211–216
  39. World Health Organization Task Force on Post-ovulatory Methods for Fertility Regulation . Lowering the doses of mifepristone and gameprost for early abortion: a randomised controlled trial. BJOG. 2001;108:738–742
  40. Ho PC, Ngai SW, Liu KL, Wong GC, Lee SW. Vaginal misoprostol compared with oral misoprostol in termination of second-trimester pregnancy. Obstet Gynecol. 1997;90:735–738
  41. Arvidsson C, Hellborg M, Gemzell-Danielsson K. Preference and acceptability of oral versus vaginal administration of misoprostol in medical abortion with mifepristone. Eur J Obstet Gynecol Reprod Biol. 2005;123:87–91
  42. Tang OS, Chan CC, Ng EH, Lee SW, Ho PC. A prospective, randomized, placebo-controlled trial on the use of mifepristone with sublingual or vaginal misoprostol for medical abortions of less than 9 weeks gestation. Hum Reprod. 2003;18:2315–2318
  43. Henderson J, Hwang A, Harper C, Stewart F. Safety of mifepristone abortions in clinical use. Contraception. 2005;72:175–178
  44. Kawonga M, Blanchard K, Cooper D, Cullingworth L, Dickson K, Harrison T, et al. Integrating medical abortion into safe abortion services: experience from three pilot sites in South Africa. J Fam Plann Reprod Health Care. 2008;34:159–164
  45. Coyaji K. Early medical abortion in India: three studies and their implications for abortion services. J Am Med Wom Assoc. 2000;55(3 Suppl):191–194
  46. Honkanen H, von Hertzen H. Users' perspectives on medical abortion in Finland. Contraception. 2002;65:419–423
  47. Winikoff B. Acceptabilty of medical abortion in early pregnancy. Fam Plann Perspect. 1995;27:142–148
  48. Suhonen S, Heikinheimo O, Tikka M, Haukkamaa M. The learning curve is rapid in medical termination of pregnancy–first-year results from the Helsinki area. Contraception. 2003;67:223–227
  49. Kahn JG, Becker BJ, MacIsaa L, et al. The efficacy of medical abortion: a meta-analysis. Contraception. 2000;61:29–40
  50. Reeves MF, Kudva A, Creinin MD. Medical abortion outcomes after a second dose of misoprostol for persistent gestational sac. Contraception. 2008;78:332–335
  51. Orioli IM, Castilla EE. Epidemiological assessment of misoprostol teratogenicity. Br J Obstet Gynaecol. 2000;107:519–523
  52. Gary MM, Harrison DJ. Analysis of severe adverse events related to the use of mifepristone as an abortifacient. Ann Pharmacother. 2006;40(4):784
  53. Allen RH, Westhoff C, De Nonno L, Fielding SL, Schaff EA. Curettage after mifepristone-induced abortion: frequency, timing, and indications. Obstet Gynecol. 2001;98:101–106
  54. Centers for Disease Control and Prevention (CDC) . Clostridium sordellii toxic shock syndrome after medical abortion with mifepristone and intravaginal misoprostol — United States and Canada, 2001–2005. MMWR. 2005;54:724
  55. Fischer M, Bhatnagar J, Guarner J, et al. Fatal toxic shock syndrome associated with Clostridium sordellii after medical abortion. NEJM. 2005;353:2352–2360
  56. Cohen AL, Bhatnagar J, Reagan S, et al. Toxic shock associated with Clostridium sordellii and Clostidium perfringens after medical and spontaneous abortion. Obst Gynecol. 2007;110:1027–1033
  57. Sawaya GF, Grady D, Kerlikowske K, Grimes DA. Antibiotics at the time of induced abortion: the case for universal prophylaxis based on a meta-analysis. Obstet Gynecol. 1996;87(5 Pt 2):884–890
  58. Baulieu EE. Deaths from Clostridium sordellii after medical abortion. NEJM. 2006;354:1645–1647
  59. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm111341.htm [accessed September 20, 2009].
  60. Fjerstad M, Trussell J, Sivin I, Lichtenberg ES, Cullins V. Rates of serious infection after changes in regimens for medical abortion. NEJM. 2009;361:145–151
  61. Finer LB, Henshaw SK. Abortion incidence and services in the United States in 2000. Perspect Sexual Reprod Health. 2003;35:6–15
  62. Faucher P, Baunot N, Madelenat P. The efficacy and acceptability of mifepristone medical abortion with home administration misoprostol provided by private providers linked with the hospital: a prospective study of 433 patients. [French] Gynecol Obstet Fertil. 2005;33:220–227
  63. Gemperli MP, Stewart FH, Phillips KA, Sakowski J, Van Bebber S, Bergthold L. A qualitative study of insurers' coverage for mifepristone-induced abortion. Managed Care Interface 2005;18:26--30, 32.
  64. Hwang AC, Koyama A, Taylor D, Henderson JT, Miller S. Advanced practice clinicians' interest in providing medical abortion: results of a California survey. Perspect Sex Reprod Health. 2005;37:92–97
  65. Leeman L, Asaria S, Espey E, Ogburn J, Gopman S, Barnett S. Can mifepristone medication abortion be successfully integrated into medical practices that do not offer surgical abortion?. Contraception. 2007;76:96–100
  66. Schwarz EB, Luetkemeyer A, Foster DG, Weitz TA, Lindes D, Stewart FH. Willing and able? Provision of medication for abortion by future internists. Womens Health Issues. 2005;15:39–44
  67. Gomperts RJ, Jelinska K, Davies S, Gemzell-Danielsson K, Kleiverda G. Using telemedicine for termination of pregnancy with mifepristone and misoprostol in settings where there is no access to safe services. BJOG. 2008;115:1171–1175
  68. Cheng L, Gulmezoglu AM, Piaggio G, Ezcurra E, Van Look PF. Interventions for emergency contraception. Cochrane Database Syst Rev. 2008;(2):CD001324
  69. Bracken H, Ngoc NT, Schaff E, et al. Mifepristone followed in 24 hours to 48 hours by misoprostol for late first-trimester abortion. Obstet Gynecol. 2007;109:895–901
  70. Hamoda H, Ashok PW, Flett GM, Templeton A. A randomised controlled trial of mifepristone in combination with misoprostol administered sublingually or vaginally for medical abortion up to 13 weeks of gestation. BJOG. 2005;118:1102–1108
  71. Hamoda H, Ashok PW, Flett GM, Templeton A. A randomized trial of mifepristone in combination with misoprostol administered sublingually or vaginally for medical abortion at 13-20 weeks gestation. Hum Reprod. 2005;20:2348–2354
  72. Bartley J, Baird DT. A randomised study of misoprostol and gemeprost in combination with mifepristone for induction of abortion in the second trimester of pregnancy. BJOG. 2002;109:1290–1294
  73. Coughlin LB, Roberts D, Haddad NG, Long A. Medical management of first trimester miscarriage (blighted ovum and missed abortion): is it effective?. J Obstet Gynaecol. 2004;24:69–71
  74. Wagaarachchi PT, Ashok PW, Narvekar NN, Smith NC, Templeton A. Medical management of late intrauterine death using a combination of mifepristone and misoprostol. BJOG. 2002;109:443–447
  75. Cohn M, Stewart P. Pretreatment of the primigravid uterine cervix with mifepristone 30 h prior to termination of pregnancy: a double-blind study. Br J Obstet Gynaecol. 1991;98:778–782
  76. World Health Organization Task Force on Post-Ovulatory Methods of Fertility Regulation . Menstrual regulation by mifepristone plus prostaglandin: results from a multicentre trial. Hum Reprod. 1995;10:308–314
  77. DeBattista C, Belanoff J, Glass S, et al. Mifepristone versus placebo in the treatment of psychosis in patients with psychotic major depression. Biol Psych. 2006;60:1343–1349
  78. Johanssen S, Allolio B. Mifepristone (RU 486) in Cushing's syndrome. Eur J Endocrinol. 2007;157:561–569
  79. Schafer EA, Venkatachari NJ, Ayyavoo V. Antiviral effects of mifepristone on human immunodeficiency virus type-1 (HIV-1): targeting Vpr and its cellular partner, the glucocorticoid receptor (GR). Antiviral Res. 2006;72:224–232
  80. Eisinger SH, Bonfiglio T, Fiscella K, et al. Twelve-month safety and efficacy of low-dose mifepristone for uterine myomas. J Minimally Invasive Gynecol. 2005;12:227–233
  81. Spitz IM, Grunberg SM, Chabbert-Buffet N, et al. Management of patients receiving long-term treatment with mifepristone. Fertil Steril. 2005;84:1719–1726
  82. Koivisto-Korander R, Leminen A, Heikinheimo O. Mifepristone as treatment of recurrent progesterone receptor-positive uterine leiomyosarcoma. Obstet Gynecol. 2007;109(2 Pt 2):512–514
  83. Bygdeman M, Danielsson KG, Marions L. Medical termination of early pregnancy: the Swedish experience. J Am Med Womens Assoc 2000;55(3 Suppl):195--6, 204.

PII: S0010-7824(09)00382-5

doi: 10.1016/j.contraception.2009.08.004

Contraception
Volume 81, Issue 1 , Pages 1-7 , January 2010

Article Tools